Actualités marché

FRANKFURT (Reuters) - U.S. health regulators on Friday approved Qiagen NV's gene-testing kit to identify those colorectal cancer patients most likely to benefit from Amgen Inc's drug, Vectibix, Qiagen

The US Food and Drug Administration on Wednesday approved the Immucor Precise Type Human Erythrocyte Antigen Molecular BeadChip Test for determining blood compatibility.

In a statement the FDA said the test is the first molecular assay to be approved by the agency for use in transfusion medicine to help in determining blood compatibility. The assay can be used to determine donor and patient non-ABO/non-RhD red blood cell types...

Qiagen has purchased the assets of Biobase, a Wolfenbüttel, Germany-based provider of curated biological databases.

SAN FRANCISCO (Reuters) - Apple Inc is building a team of senior medical technology executives, raising hackles in the biotechnology community and offering a hint of what the iPhone maker may be planning for its widely expected iWatch and other wearable technology....Much of the hiring is in sensor technology...

Le groupe de diagnostic in vitro bioMérieux a annoncé lundi avoir obtenu le feu vert de l'agence américaine du médicament (FDA) pour la mise sur le marché aux Etats-Unis de son nouveau test gastro-intestinal FilmArray, développé par la société BioFire Diagnostics.
FilmArray est un système de diagnostic moléculaire qui permet d'identifier en un seul réactif les pathogènes, d'origine virale ou bactérienne, responsables d'une infection gastro-intestinale.

A startup called BaseHealth launched on Tuesday with a mission to deliver personalized wellness plans while keeping doctors very much in the picture. The company’s platform combines genetic data, lifestyle data and medical records to determine patients’ risks and how they can mitigate them.

GENSIGNIAGENSIGNIA :: novel diagnostic clinical tests for earlier and more accurate early detection of lung cancer

PerkinElmer has decided to close its Signature Genomics cytogenetic testing services business.

A company spokesperson told GenomeWeb Daily News that effective May 2, PerkinElmer is "exiting its microarray service business, Signature Genomics, which provides diagnostic genetic testing services using microarrays."

PerkinElmer cited "changing market conditions, including a highly unfavorable reimbursement environment, combined with a significant decline in demand for invasive procedures due to the uptake of non-invasive prenatal testing" as reasons for its decision.

Enigma Diagnostics and China's ICDC Announce Collaboration to Develop MDx Infectious Disease Assays on Enigma ML system for use at Point-of-Care...

The Enigma ML's highly accurate and multiplex assay reporting capabilities enables testing for the widest range of DNA and RNA disease targets with a fast turnaround time. The unique features of the system offer a hybrid laboratory and stand-alone diagnostic testing platform, designed to be of use in developed and emerging healthcare programmes.

 CareDx, formerly called XDx, said late Wednesday that it has reached an agreement to acquire transplant diagnostic company ImmuMetrix.

Total hemoglobin concentration is said to be the most common laboratory test ordered in medical offices and hospital settings. It is used to determine the presence of anemia, functionally defined as insufficient oxygen-carrying capacity of the blood.

In keeping with the trend of incorporating sophisticated technology into easily used point-of-care devices, many manufacturers provide products that offer prompt assessment of hemoglobin levels. Point-of-care hemoglobin testing is being increasingly used to provide rapid results in many clinical settings, including the perioperative setting, where it enables rapid decision-making for administering red blood cell transfusions.

Enigma Diagnostics today said that it will collaborate with China’s National Institute for Communicable Disease Control and Prevention on the development of rapid molecular diagnostics for infectious disease pathogens...The collaboration is a cornerstone achievement in our China strategy and our broader commercialisation programme and follows on from the European CE mark registration of the Enigma ML system in January this year.

BioMérieux today announced that BioFire's FilmArray Gastrointestinal Panel has received 510(k) clearance for marketing by the US Food and Drug Administration.

The 22-target panel is for diagnosing infectious diarrhea and includes bacteria, viruses, and parasites in one test. According to BioMérieux, the test is the most comprehensive gastrointestinal panel to be cleared by FDA and contains several pathogens that have received FDA clearance for the first time...

The County Antrim-based healthcare diagnostics company, Randox, announces a significant expansion after acquiring a laboratory in Manchester.

Diaxonhit a annoncé l'obtention d'une aide financière de 1 728 000 euros de Bpifrance, dans le cadre de sa participation au consortium de recherche mené par InnaVirVax et financé sous l'égide du programme « Innovation Stratégique Industrielle ».